The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Nov. 23, 2021
Applicant:

Therapeutic Solutions International, Inc., Oceanside, CA (US);

Inventors:

Thomas Ichim, Oceanside, CA (US);

Timothy G. Dixon, Oceanside, CA (US);

Famela Ramos, Oceanside, CA (US);

Wais Kaihani, Oceanside, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 36/82 (2006.01); A61K 31/09 (2006.01); A61K 31/122 (2006.01); A61K 31/155 (2006.01); A61K 31/26 (2006.01); A61K 31/352 (2006.01); A61K 36/31 (2006.01); A61K 36/45 (2006.01); A61K 36/71 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01);
U.S. Cl.
CPC ...
A61K 36/82 (2013.01); A61K 31/09 (2013.01); A61K 31/122 (2013.01); A61K 31/155 (2013.01); A61K 31/26 (2013.01); A61K 31/352 (2013.01); A61K 36/31 (2013.01); A61K 36/45 (2013.01); A61K 36/71 (2013.01); A61P 37/04 (2018.01);
Abstract

Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of pterostilbene,extract, green tea extract, and broccoli. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene,, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.


Find Patent Forward Citations

Loading…